ChemBridge

GSK Extends Strategic Collaboration with Aspen

Date Posted: Thursday, May 14, 2009

Print Email to a friend

GlaxoSmithKline plc (GSK) has announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company. This is part of a wide ranging agreement which includes combining commercial activities in Sub-Saharan Africa and the divestment of several assets to Aspen.

Abbas Hussain, President Emerging Markets, GlaxoSmithKline said: "Extending our strategic relationship with Aspen supports GSK's strategy to accelerate sales growth in emerging markets. The combination of our commercial activities in Sub-Saharan Africa is highly complementary and will mean that together we can provide more medicines of value to more patients in these countries. At the same time, GSK will also benefit from investing in one of Africa's leading healthcare companies with a formidable track record of delivery."

On completion, Aspen will issue 68.5 million new shares as non-cash consideration to GSK in exchange for the transfer of several assets. These shares will be equivalent to a 16% shareholding in the company; and Aspen has a current total market capitalization value of 1.4 billion pounds Sterling. As part of the agreement and on closure of the transaction, Aspen will appoint a non-executive director, nominated by GSK, to its Board of Directors.

Specialist products and manufacturing facility divested to Aspen.

GSK will divest eight specialist medicines to Aspen and a manufacturing facility located in Bad Oldesloe, Germany. The products to be divested are Alkeran (excluding US), Kemadrin, Lanvis, Leukeran, Myleran, Purinethol, Septrin and Trandate. Combined sales of these products were 56 million pounds Sterling in 2008. The Bad Oldesloe manufacturing site produces some of the products to be divested and a number of other products previously acquired by Aspen from GSK in June 2008.

These divestments reflect GSK's strategy to simplify its operations and divest certain products which can be commercialized by other parties.

Further Information: http://www.gsk.com/



Related news from our archive

GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
Creates a new focused HIV business with the independence and sustainability to deliver improvements in treatment, access and shareholder value.

Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
GSK will not exercise its option to license ispinesib or SB-743921 as provided under the collaboration agreement with Cytokinetics entered in 2001.

GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory Diseases
The alliance leverages Archemix’s expertise in the discovery and development of Aptamers and provides GSK with an option to license product candidates.

Ligand Enters into Exclusive License Agreement with GlaxoSmithKline for Thrombopoietin Related Molecules
Ligand has licensed worldwide exclusive rights to its LGD-4665 product candidate and its other thrombopoietin related molecules to GSK.

GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
Creates a new focused HIV business with the independence and sustainability to deliver improvements in treatment, access and shareholder value.

Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
GSK will not exercise its option to license ispinesib or SB-743921 as provided under the collaboration agreement with Cytokinetics entered in 2001.

GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory Diseases
The alliance leverages Archemix’s expertise in the discovery and development of Aptamers and provides GSK with an option to license product candidates.

Ligand Enters into Exclusive License Agreement with GlaxoSmithKline for Thrombopoietin Related Molecules
Ligand has licensed worldwide exclusive rights to its LGD-4665 product candidate and its other thrombopoietin related molecules to GSK.

GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance
The collaboration is aimed at developing first-in-class endosomal Toll-like Receptors inhibitors for autoimmune and inflammatory diseases.

GlaxoSmithKline to Acquire Genelabs to Increase Focus on Small Molecule Therapies for Hepatitis C
Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock.

GlaxoSmithKline Signs Licensing Agreement with Compendia Bioscience
Compendia has signed a two-year licensing agreement with GSK for Oncomine Enterprise Edition.

GlaxoSmithKline Uses Clinical Graphics Solution Developed by Insightful Corporation
GSK using Insightful’s clinical graphics solution for communicating safety and efficacy information in clinical data.

Glaxosmithkline Renews and Expands Global License for Simulations Plus Software
GSK renews its global multi-year license for Simulations Plus software and adds a new site at its Parsippany, NJ location.

GlaxoSmithKline Extends GeneGo License and Adds New Products
The extended licensing agreement provides GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase.

GSK Extends GeneGo License and Adds new Products
This will provide GSK researchers in Bioinformatics, R&D; and clinical studies with global access to MetaCore, MapEditor and MetaBase.

GSK and MRC to Identify new Therapeutic Targets and Biomarkers from Genetic Association Studies
Both parties have announced the creation of a jointly funded programme seeking to identify and validate genes associated with common human diseases.